RecruitingNCT06367582

Spine Bone Cements Outcomes - Post Market Follow-up

Safety and Clinical Performance Assessment of Bone Cements and Injection Systems Used in Spine Surgery - A Post-Market Clinical Follow-Up


Sponsor

Teknimed

Enrollment

500 participants

Start Date

Sep 4, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

A Post-Market Clinical Follow-Up (PMCF) Study to collect clinical data on safety and performance of all TEKNIMED Spine range of products: SPINEFIX, HIGH V+, OPACITY+ and F20 bone cements and mixing and injection systems, and all their private labels. TEKNIMED bone cements are legacy products, some marketed for more than 10 years. Their performance and safety have already been demonstrated by Post-Market Surveillance and previous clinical studies. The current Post-Market Clinical Follow-Up study aims to confirm these claims by collecting data in a "real-life" setting. The study is a retrospective and prospective global, single arm, non-controlled, multicentric, prospective observational study. Patients will be followed as per local standard medical care of the sites.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Be 18 years or older
  • Be willing to sign an informed consent approved by Ethic Committee (when applicable) or not being opposed to the use of their clinical data in the study
  • Be considered for treatment with one of the TEKNIMED Spine Range cement comprised in this study
  • Have undergone a surgery with a TEKNIMED Spine Range cement between the 1st of January 2016 and the date of the site initiation visit.
  • Be informed of the study and not being opposed to the use of their clinical data in the study or be willing to sign an informed consent during the first follow-up visit following the site initiation (when applicable).

Exclusion Criteria9

  • Patients presenting one of the following conditions will not be included (contraindications per IFU):
  • Procedures other than those stated in the INDICATIONS section
  • Coagulation disorders, or severe cardiopulmonary disease
  • Unstable vertebral fractures
  • Compromise of the vertebral body or of the pedicle walls
  • Hypersensitivity or allergy to one of the constituents of the product
  • Patient clearly improving on more conservative treatment
  • Prophylactic use in spinal metastatic or osteoporotic patients with no evidence of acute fracture
  • Paediatric patients and pregnant or breast-feeding women.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVertebroplasty (VP)

Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

DEVICEKyphoplasty (KP)

Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

DEVICEPedicular Screw Augmentation (PSA)

Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength


Locations(12)

CHU HautePierre

Strasbourg, Bas-Rhin, France

Pôle Rachis Hôpital Privé d'Eure et Loir

Mainvilliers, Eure et Loir, France

Hôpital Toulouse Purpan

Toulouse, Haute Garonne, France

Pôle Sud Santé

Le Mans, Sarthe, France

Centre Hospitalier Métropole Savoie

Chambéry, Savoie, France

Hospitale Cruz Vermelha Portuguesa

Lisbon, Portugal

Clínica Teknon Instituto de neurociencias

Barcelona, Spain

Hospital Neurotraumatologico

Granada, Spain

Hospital Clínico Universitario Virgen de la Arrixaca

Murcia, Spain

Fundacio Assistencial Mutua de Terrassa - Edifici Estació

Terrassa, Spain

Hospital de Zafra

Zafra, Spain

Institute of Traumatology and Orthopaedics

Kiev, Ukraine

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06367582


Related Trials